At what enterprise value was BIO PRODUCTS LABORATORY (BPL) acquired in 2022?

You can find the full valuation details of BIO PRODUCTS LABORATORY (BPL) on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of BIO PRODUCTS LABORATORY (BPL) when it was acquired by PERMIRA?

The exact EV/EBITDA multiple for BIO PRODUCTS LABORATORY (BPL) is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was BIO PRODUCTS LABORATORY (BPL) acquired by PERMIRA?

BIO PRODUCTS LABORATORY (BPL) was acquired by PERMIRA in 2022.

What was the revenue of BIO PRODUCTS LABORATORY (BPL) at the time of the deal?

The revenue of BIO PRODUCTS LABORATORY (BPL) at the time of the deal is estimated to be in the range of 250M - 500M GBP. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the BIO PRODUCTS LABORATORY (BPL) acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the BIO PRODUCTS LABORATORY (BPL) deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.permira.com/news-and-insights/announcements/permira-funds-to-partner-with-marcucci-family-to-invest-in-kedrion-biopharma-and-bio-products-laboratory

← DATABASE

Home Database Healthcare & PharmaBIO PRODUCTS LABORATORY (BPL)

01/2022

BIO PRODUCTS LABORATORY (BPL) acquired by PERMIRA

UNITED KINGDOM Life Sciences / Pharma & Biotech / CDMO REV 250M - 500M GBP

Context

Permira acquired BPL from its sole shareholder, Tiancheng International Investment (TII), which had owned the business since 2016. The acquisition was part of a larger strategic plan to merge BPL's robust US collection network and specialized rare disease portfolio with Kedrion. By detaching BPL from its Chinese parent company, Permira allowed the business to refocus on its core UK and US markets. The combination created massive synergies in fractionation capacity and plasma supply, solving long-standing raw material bottlenecks for the UK-based manufacturing facilities.

BIO PRODUCTS LABORATORY (BPL), which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

BPL is a pioneer in the plasma industry, primarily focused on the development and manufacture of rare disease therapies. It operates two divisions: BPL Plasma (operating ~29 collection centers in the US) and BPL Therapeutics (manufacturing in the UK). Its products treat immune deficiencies, bleeding disorders, and infectious diseases.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
03/2022	FRESENIUS	MABXIENCE	SPAIN	CDMO
02/2022	MONTAGU PRIVATE EQUITY / PARTNERS GROUP	HTL BIOTECHNOLOGY	FRANCE	CDMO
01/2022	PERMIRA	KEDRION	ITALY	CDMO
01/2022	ANJAC BEAUTY & HEALTH	APOLLO HEALTHCARE CORP.	CANADA	CDMO
01/2022	ARDIAN	BIOFARMA GROUP	ITALY	CDMO
12/2021	PLANMECA GROUP	KAVO DENTAL	GERMANY	Medical Devices
12/2021	THE CARLYLE GROUP / GTCR	RESONETICS	UNITED STATES	Medical Devices
12/2021	INTEGER	OSCOR	UNITED STATES	Implants & Prosthetics
12/2021	WINNCARE	PHARMAOUEST INDUSTRIES	FRANCE	Medical Devices
11/2021	COLOPLAST	ATOS MEDICAL	SWEDEN	Medical Consumables

REFERENCES

Revenue range: 250M - 500M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of BIO PRODUCTS LABORATORY (BPL) by PERMIRA are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: permira